ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Development and Validation of the PREMM
Open access · greenAbstract read
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 2 pooled it
11.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Guideline
- Collaborative Group of the Americas on Inherited Gastrointestinal Cancer Position statement on multigene panel testing for patients with colorectal cancer and/or polyposis.Familial cancer · 2020Guideline
- Cancer Health Assessments Reaching Many (CHARM): A clinical trial assessing a multimodal cancer genetics services delivery program and its impact on diverse populations.Contemporary clinical trials · 2021Trial
- Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting.Familial cancer · 2019Trial
- Pan-cancer prevalence of microsatellite instability and Lynch syndrome in India.Familial cancer · 2026Article
- Outcomes of 'in-house' genetic testing within a specialist hereditary colorectal cancer registry.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
- Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.Nature reviews. Urology · 2026Review
- From theory to practice: improving Lynch syndrome recognition through evidence-based education.Familial cancer · 2026Review
- Quantifying the role of communication in recruitment status outcomes for a clinical trial on genetic testing uptake.Contemporary clinical trials · 2026Article
- Characterization of a novel MSH2 variant in Lynch syndrome: clinical data and complementary bioinformatics assessment.Einstein (Sao Paulo, Brazil) · 2026Article
- Article
- Lynch Syndrome in Focus: A Multidisciplinary Review of Cancer Risk, Clinical Management, and Special Populations.Cancers · 2025Review
- Article
- Predictors of Genetic Testing for Hereditary Cancer in Qualified Individuals.Medical research archives · 2025Article
- Genomics and integrative clinical data machine learning scoring model to ascertain likely Lynch syndrome patients.BJC reports · 2025Article
- Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma.Cancer medicine · 2025Review
- Article
- Lynch Syndrome-Impact of the Type of Deficient Mismatch Repair Gene Mutation on Diagnosis, Clinical Presentation, Surveillance and Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2025Review
- Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome.JCO precision oncology · 2025Article
- Gynecological Insights into Lynch Syndrome-A Comprehensive Review of Cancer Screening and Prevention.Medicina (Kaunas, Lithuania) · 2024Review
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Fay KastrinosFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Hajime UnoFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Chinedu UkaegbuFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Carmelita AlveroFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Ashley McFarlandFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Matthew B YurgelunFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Matthew H KulkeFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Deborah SchragFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Jeffrey A MeyerhardtFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Charles S FuchsFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Robert J MayerFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Kimmie NgFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Ewout W SteyerbergFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Sapna SyngalFay Kastrinos and Ashley McFarland, Columbia University Medical Center, New York, NY; Hajime Uno, Chinedu Ukaegbu, Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Dana-Farber Cancer Institute; Carmelita Alvero, Harvard T.H. Chan School of Public Health; Matthew B. Yurgelun, Matthew H. Kulke, Deborah Schrag, Jeffrey A. Meyerhardt, Charles S. Fuchs, Robert J. Mayer, Kimmie Ng, and Sapna Syngal, Harvard Medical School; Sapna Syngal, Brigham and Women's Hospital, Boston, MA; and Ewout W. Steyerberg, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Institute of Cancer Research · GB
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MValidation and extension of the PREMM Model for mismatch repair gene mutationsR01CA132829 · NCI · DANA-FARBER CANCER INST · PI SYNGAL, SAPNA · 2008 to 2022
$5.6MImpact of Celecoxib and Inflammation on Survival in Stage III Colon CancerR01CA169141 · NCI · YALE UNIVERSITY · PI FUCHS, CHARLES S · 2013 to 2018
$3.9MThe Genetics and Prevention of Gastrointestinal CancersK24CA113433 · NCI · DANA-FARBER CANCER INSTITUTE · PI SYNGAL, SAPNA · 2005 to 2014
$1.7MAssessment of Inherited Colon Cancer Prediction Models in Diverse PopulationsK07CA151769 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KASTRINOS, FAY · 2010 to 2014
$855kPartnerships Between Medicaid, Tumor Registries & Cancer Control ResearchersK05CA169384 · NCI · DANA-FARBER CANCER INST · PI SCHRAG, DEBORAH · 2012 to 2016
$586kStatistical analysis methods for validating risk prediction modelsR21CA185704 · NCI · DANA-FARBER CANCER INST · PI UNO, HAJIME · 2014 to 2015
$414kNCATS NIH HHS UL1 TR001863NCI NIH HHS K05 CA169384NCI NIH HHS K07 CA151769NCI NIH HHS K24 CA113433NCI NIH HHS R01 CA132829NCI NIH HHS R01 CA169141NCI NIH HHS R21 CA185704
Abstract
Purpose Current Lynch syndrome (LS) prediction models quantify the risk to an individual of carrying a pathogenic germline mutation in three mismatch repair (MMR) genes: MLH1, MSH2, and MSH6. We developed a new prediction model, PREMM
Indexed as
Models, GeneticCohort StudiesColorectal Neoplasms, Hereditary NonpolyposisDNA-Binding ProteinsEpithelial Cell Adhesion MoleculeFemaleGenetic Predisposition to DiseaseGerm-Line MutationHumansLogistic ModelsMaleMiddle AgedMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinPredictive Value of TestsDNA-Binding ProteinsEPCAM protein, humanEpithelial Cell Adhesion MoleculeG-T mismatch-binding proteinMismatch Repair Endonuclease PMS2MLH1 protein, humanMSH2 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinPMS2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.